NO20073211L - Tibulinbindende anti-cancerstoffer og promedikamenter av disse - Google Patents
Tibulinbindende anti-cancerstoffer og promedikamenter av disseInfo
- Publication number
- NO20073211L NO20073211L NO20073211A NO20073211A NO20073211L NO 20073211 L NO20073211 L NO 20073211L NO 20073211 A NO20073211 A NO 20073211A NO 20073211 A NO20073211 A NO 20073211A NO 20073211 L NO20073211 L NO 20073211L
- Authority
- NO
- Norway
- Prior art keywords
- tibulin
- promedics
- cancer drugs
- binding anti
- new
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 229940041181 antineoplastic drug Drugs 0.000 title 1
- 102000004243 Tubulin Human genes 0.000 abstract 2
- 108090000704 Tubulin Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63042204P | 2004-11-22 | 2004-11-22 | |
| US72692805P | 2005-10-14 | 2005-10-14 | |
| PCT/US2005/042095 WO2006057946A2 (en) | 2004-11-22 | 2005-11-17 | Tubulin binding anti cancer agents and prodrugs thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20073211L true NO20073211L (no) | 2007-08-21 |
Family
ID=36498450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20073211A NO20073211L (no) | 2004-11-22 | 2007-06-22 | Tibulinbindende anti-cancerstoffer og promedikamenter av disse |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090042820A1 (enExample) |
| EP (1) | EP1819338A4 (enExample) |
| JP (1) | JP2008520719A (enExample) |
| KR (1) | KR20070086595A (enExample) |
| AU (1) | AU2005309761A1 (enExample) |
| CA (1) | CA2587210A1 (enExample) |
| IL (1) | IL183212A0 (enExample) |
| MX (1) | MX2007006102A (enExample) |
| NO (1) | NO20073211L (enExample) |
| WO (1) | WO2006057946A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200507752B (en) | 2003-03-28 | 2007-01-31 | Threshold Pharmaceuticals Inc | Compositions and methods for treating cancer |
| ZA200800314B (en) | 2005-06-29 | 2009-09-30 | Threshold Pharmaceuticals Inc | Phosphoramidate alkylator prodrugs |
| CN101506158A (zh) * | 2006-06-28 | 2009-08-12 | 株式会社三和化学研究所 | 新6-5系二环式杂环衍生物及其医药用途 |
| US8552048B2 (en) | 2006-12-26 | 2013-10-08 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs for the treatment of cancer |
| US8765690B2 (en) | 2007-04-05 | 2014-07-01 | Threshold Pharmaceuticals, Inc. | Treatment of cancer with glufosfamide in patients not receiving insulin therapy |
| WO2008151253A1 (en) * | 2007-06-04 | 2008-12-11 | Threshold Pharmaceuticals, Inc. | Hypoxia activated prodrugs of antineoplastic agents |
| WO2010048330A1 (en) | 2008-10-21 | 2010-04-29 | Threshold Pharmaceuticals, Inc. | Treatment of cancer using hypoxia activated prodrugs |
| FR2962437B1 (fr) * | 2010-07-06 | 2012-08-17 | Sanofi Aventis | Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique |
| EP2697203B1 (en) * | 2011-04-13 | 2017-05-24 | Merck Sharp & Dohme Corporation | Mineralocorticoid receptor antagonists |
| JP5922791B2 (ja) | 2012-10-29 | 2016-05-24 | 京セラ株式会社 | 弾性表面波センサ |
| CA2924843A1 (en) * | 2013-09-27 | 2015-04-02 | Allergan, Inc. | Compounds and methods for skin repair |
| WO2015123424A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| LT3105218T (lt) | 2014-02-13 | 2019-12-10 | Incyte Corp | Ciklopropilaminai kaip lsd1 inhibitoriai |
| EP3392244A1 (en) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
| WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| WO2016011195A1 (en) | 2014-07-17 | 2016-01-21 | Threshold Pharmaceuticals, Inc. | Th-302 solid forms and methods related thereto |
| WO2016145092A1 (en) | 2015-03-10 | 2016-09-15 | Threshold Pharmaceuticals, Inc. | Dna alkylating agents |
| WO2016161342A2 (en) * | 2015-04-02 | 2016-10-06 | Threshold Pharmaceuticals, Inc. | Nitrobenzyl derivatives of anti-cancer agents |
| EA201792205A1 (ru) | 2015-04-03 | 2018-02-28 | Инсайт Корпорейшн | Гетероциклические соединения как ингибиторы lsd1 |
| US20180169064A1 (en) | 2015-06-24 | 2018-06-21 | Threshold Pharmaceuticals, Inc. | Aziridine containing dna alkylating agents |
| DK3334709T3 (da) | 2015-08-12 | 2025-02-03 | Incyte Holdings Corp | Salte af en lsd1-hæmmer |
| CA3021678A1 (en) | 2016-04-22 | 2017-10-26 | Incyte Corporation | Formulations of an lsd1 inhibitor |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| US11427591B2 (en) | 2018-10-17 | 2022-08-30 | Insilico Medicine Ip Limited | Kinase inhibitors |
| CN115403483B (zh) * | 2021-07-02 | 2024-01-26 | 河南省儿童医院郑州儿童医院 | 含二苯乙烯或二苯甲酮骨架的ca-4衍生物、药物组合物及其制备方法和应用 |
| CN122555695A (zh) | 2023-11-29 | 2026-08-11 | 爱克堤欧生物科学股份有限公司 | 可用作kcnt1抑制剂的杂环化合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004099139A1 (en) * | 2000-09-15 | 2004-11-18 | Baylor University | Indole-containing compounds with anti-tubulin and vascular targeting activity |
| AU4352701A (en) * | 2000-03-10 | 2001-09-24 | Univ Baylor | Tubulin binding ligands and corresponding prodrug constructs |
| FR2816938B1 (fr) * | 2000-11-22 | 2003-01-03 | Sanofi Synthelabo | Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant |
| FR2838123B1 (fr) * | 2002-04-04 | 2005-06-10 | Sanofi Synthelabo | Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf |
| FR2839718B1 (fr) * | 2002-05-17 | 2004-06-25 | Sanofi Synthelabo | Derives d'indole, leur procede de preparation et les compositions pharmaceutiques en contenant |
| DE60336646D1 (de) * | 2003-08-07 | 2011-05-19 | Nat Health Research Institutes | Indol-Verbindungen als Inhibitoren der Tubulin-Polymerisation zur Behandlung von angiogenesisbezogenen Erkrankungen |
| US7456289B2 (en) * | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
-
2005
- 2005-11-17 JP JP2007543334A patent/JP2008520719A/ja not_active Withdrawn
- 2005-11-17 AU AU2005309761A patent/AU2005309761A1/en not_active Abandoned
- 2005-11-17 US US11/791,420 patent/US20090042820A1/en not_active Abandoned
- 2005-11-17 CA CA002587210A patent/CA2587210A1/en not_active Abandoned
- 2005-11-17 WO PCT/US2005/042095 patent/WO2006057946A2/en not_active Ceased
- 2005-11-17 EP EP05826480A patent/EP1819338A4/en not_active Withdrawn
- 2005-11-17 MX MX2007006102A patent/MX2007006102A/es not_active Application Discontinuation
- 2005-11-17 KR KR1020077014342A patent/KR20070086595A/ko not_active Withdrawn
-
2007
- 2007-05-15 IL IL183212A patent/IL183212A0/en unknown
- 2007-06-22 NO NO20073211A patent/NO20073211L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006057946A2 (en) | 2006-06-01 |
| MX2007006102A (es) | 2007-07-11 |
| WO2006057946A3 (en) | 2007-07-05 |
| KR20070086595A (ko) | 2007-08-27 |
| CA2587210A1 (en) | 2006-06-01 |
| AU2005309761A1 (en) | 2006-06-01 |
| EP1819338A4 (en) | 2009-11-04 |
| JP2008520719A (ja) | 2008-06-19 |
| IL183212A0 (en) | 2008-04-13 |
| EP1819338A2 (en) | 2007-08-22 |
| US20090042820A1 (en) | 2009-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2017019I1 (no) | Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav | |
| GEAP202214922A (en) | Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof | |
| NO20092658L (no) | New compounds | |
| HRP20171337T1 (hr) | Monoklonska antitijela protiv klaudina-18 za liječenje karcinoma | |
| WO2019234241A8 (en) | ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT | |
| AU2006226897B2 (en) | Combinations for the treatment of cancer comprising anti-EGFR antibody and VEGFR inhibitors | |
| CR10679A (es) | Novel anti-cd38 antibodies for the treatment of cancer | |
| MX2007006102A (es) | Agentes anti-cancer de union a tubulina y profarmacos de los mismos. | |
| EP1844077A4 (en) | DR5 ANTIBODIES AND THEIR USE | |
| NO20070782L (no) | Tetrapeptidanaloger. | |
| NO20091661L (no) | Anvendelse av pegylert IL-10 for a behandle kreft | |
| MY159201A (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
| DK1853602T3 (da) | Kemiske forbindelser | |
| DK1734995T3 (da) | Monoklonale antistoffer og hepatocyytvækstfaktor | |
| DK1853588T3 (da) | Kemiske forbindelser | |
| ATE488232T1 (de) | P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen | |
| IL185491A0 (en) | Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer | |
| PL2109623T3 (pl) | Leczenie nowotworu przeciwciałami przeciw il-1 | |
| DE60321041D1 (de) | Antikörper gegen krebsantigen tmeff2 und seine anwendungen | |
| EA200701930A1 (ru) | Производные пиримидина для лечения гиперпролиферативных нарушений | |
| ATE445398T1 (de) | Kombinationen mit epothilonen und protein-tyrosin-kinasehemmern sowie pharamazeutische verwendung dafür | |
| ATE466841T1 (de) | 1-phenethylpiperidinderivate und ihre verwendung als opioidrezeptor-liganden | |
| NO20055307D0 (no) | Substituerte isokromanforbindelser for behandling av metabolske forstyrrelser, kreft og andre sykdommer | |
| DE60214019D1 (de) | Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren | |
| DE60231971D1 (de) | Ndet, und seine verwendung zur behandlung von krebs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |